
Mitochondrial · research grade
2S-31
Elamipretide, cardiolipin-targeting tetrapeptide. Independently verified and released in the United States.
Research & references
2S-31 (Elamipretide) →A cardiolipin-targeting tetrapeptide, developed clinically as elamipretide, which received FDA accelerated approval in 2025 for Barth syndrome.Source 1 It concentrates in the inner mitochondrial membrane and improved redox state and exercise tolerance in aged mice.Source 2 It is in phase III development for dry age-related macular degeneration and mitochondrial myopathies.Source 1 Material supplied here is research-grade and is not the approved product.